

ASX Announcement

22 May 2026

Spanish Clinical Experience with the OncoSil™ Device Accepted for Poster Presentation at ASCO Annual Meeting 2026

Highlights

- Abstract featuring Spanish multi-centre experience with the OncoSil™ device accepted for a poster presentation at American Society of Clinical Oncology (ASCO) Annual Meeting 2026, to be held 29 May – 2 June 2026 in Chicago, United States
- Data to be presented by Dr Carmen Guillen-Ponce from Hospital Universitario Ramón y Cajal, Madrid, Spain on 30 May 2026
- Data highlights excellent safety of OncoSil™ device, with a high percentage of surgical resection rates achieved in LAPC patients deemed unresectable at diagnosis
- Case report published in *Cureus* journal highlighted patient with unresectable LAPC treated with OncoSil™ device + standard of care chemotherapy was successfully surgically resected and remains alive 50 months post diagnosis

Sydney, Australia – 22 May 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that an abstract highlighting the Spanish clinical experience with the OncoSil™ device has been accepted for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, taking place from 29 May to 2 June 2026 in Chicago, United States. The data will be presented by Dr. Carmen Guillen-Ponce on 30 May 2026 in the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary session.

The ASCO Annual Meeting is one of the world’s leading oncology congresses, bringing together global experts to share the latest advances in cancer research and treatment. Acceptance of this abstract reflects growing international clinical interest in the role of the OncoSil™ device as a treatment option for patients with unresectable LAPC.

The accepted abstract is titled: *“Experience of Spanish centers with echoendoscopically implanted ³²P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma”*

The abstract reports outcomes from 51 patients with unresectable locally advanced pancreatic cancer treated across Spanish centres with OncoSil™ device delivered via endoscopic ultrasound (EUS).

Key findings included:

- The treatment demonstrated a favourable safety profile, with only two adverse events considered related to the OncoSil™ treatment relating to mild gastric pain and weakness.
- Seven patients (13.7%) initially considered unresectable subsequently underwent surgery, including five R0 resections (i.e. patients had completely clear surgical margins devoid of cancerous cells).
- Median progression-free survival (PFS) from OncoSil™ treatment was 8.5 months (95% CI 5.3–17 months).
- 33 patients are alive at the end of follow-up (64.7%) with a median OS since OncoSil™ treatment of 15.6 months (95% CI 10.2–26.9 months).

The investigators concluded that intratumoural OncoSil™ treatment in addition to gemcitabine-based chemotherapy is safe and demonstrated encouraging survival outcomes, with surgical rescue achieved in a high percentage of initially unresectable patients.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“We are pleased to see the Spanish clinical experience with the OncoSil™ device recognised at ASCO Annual Meeting 2026. Spain has become the leading country for the routine clinical adoption of OncoSil™, and is one of our most experienced markets globally, with clinicians continuing to demonstrate leadership in integrating this innovative therapy into everyday practice. The results presented in this abstract are encouraging, demonstrating a favourable safety profile, promising survival outcomes and the potential for surgical conversion in some patients initially considered unresectable. We are also encouraged by the recently published case report from Hospital Universitario de Fuenlabrada, which demonstrated successful surgical resection and long-term disease-free survival following treatment with the OncoSil™ device in a patient with initially unresectable locally advanced pancreatic cancer. We sincerely thank the Spanish investigators and treating clinicians for their commitment to improving outcomes for patients with unresectable locally advanced pancreatic cancer.”

In addition, a case report from Hospital Universitario de Fuenlabrada, Madrid, Spain, published in the peer-reviewed journal *Cureus*, described a patient with initially unresectable LAPC who subsequently underwent successful surgical resection following treatment with the OncoSil™ device in addition to gemcitabine+nab-paclitaxel chemotherapy.

Key findings included:

- The patient was initially diagnosed with unresectable pancreatic adenocarcinoma in the head of the pancreas
- OncoSil™ microparticles was administered following induction chemotherapy
- No device- or procedure-related adverse events were observed
- Disease stabilisation and tumour response enabled successful surgical resection 7.9 months after

diagnosis

- As of January 2026, the patient remained alive with no evidence of disease 50 months after diagnosis and 42 months post-resection
- The authors concluded that the addition of OncoSil™ microparticles to first-line chemotherapy was associated with disease stabilisation and conversion to surgical resection in this patient with unresectable locally advanced pancreatic cancer

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981</p>	<p>Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079</p>
---	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Australia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>